论文部分内容阅读
背景与目的:高剂量化放疗联合自体造血干细胞移植(autologoushematopoieticstemcellstransplantation,AHSCT)能够提高某些实体瘤的疗效,该疗法的成功得益于重组人粒细胞集落刺激因子(recombinanthumangranulocytecolony-stimulatingfactor,rhG-CSF)的运用。本研究的目的是观察rhG-CSF对实体瘤患者自体造血干细胞移植后造血功能重建的影响。方法:将接受AHSCT的130例实体瘤患者分为rhG-CSF组和对照组,rhG-CSF组在造血干细胞回输后第6天开始连日给予rhG-CSF250～300μg/d,皮下注射,直至白细胞(whitebloodcell,WBC)≥5.0×109/L为止;对照组在造血干细胞回输后不给予rhG-CSF。结果:130例患者共完成移植132次,其中2例为2次移植。研究早期的24例患者采取自体骨髓移植,其中12例移植后给予rhG-CSF;此后的106例均采用自体外周血造血干细胞移植(2例为2次移植),其中47例移植后给予rhG-CSF。(1)rhG-CSF组和对照组自体骨髓移植患者住无菌病房的中位时间为33天和41天,WBC恢复到1.5×109/L以上的中位时间为14天和24天,两组之间的差异有显著性(P<0.05);两组血小板(platelet,PLT)恢复到20×109/L及50×109/L以上的中位时间均无显著性差异。(2)rhG-CSF组和对照组自体外周血干细胞移植患者住无菌病房的中位时间为17天和20天,
BACKGROUND & OBJECTIVE: High dose radiation combined with autologous hematopoietic stem cell transplantation (AHSCT) can improve the curative effect of some solid tumors. The success of this therapy is attributed to recombinant human granulocyte-stimulating factor (rhG-CSF) The use of. The purpose of this study was to investigate the effect of rhG-CSF on hematopoietic reconstitution following autologous hematopoietic stem cell transplantation in solid tumor patients. Methods: One hundred and thirty solid tumors from AHSCT patients were divided into rhG-CSF group and control group. RhG-CSF group received rhG-CSF 250-300μg / d on the sixth day after hematopoietic stem cell reinfusion and injected subcutaneously until leukocyte (whitebloodcell, WBC) ≥5.0 × 109 / L; control group did not give rhG-CSF after hematopoietic stem cell reinfusion. Results: 130 patients completed a total of 132 transplants, of which 2 were 2 transplants. Autologous bone marrow transplantation was performed in 24 patients in the early study. Twelve of the patients were given rhG-CSF after transplantation. All the 106 patients were treated with autologous peripheral blood stem cell transplantation (two patients were transplanted twice), of which 47 patients were given rhG- CSF. (1) The median time to live sterility wards of autologous bone marrow transplant patients in rhG-CSF group and control group was 33 days and 41 days, and the median time for WBC to recover above 1.5 × 109 / L was 14 days and 24 days. There was significant difference between the two groups (P <0.05). There was no significant difference between the two groups in platelet (PLT) recovery to the median of 20 × 109 / L and 50 × 109 / L. (2) The median time spent on sterile ward in patients with autologous peripheral blood stem cell transplantation in rhG-CSF group and control group was 17 days and 20 days,